Regenerative Solutions.

To play, press and hold the enter key. To stop, release the enter key.

Revolutionary Care.

Who We Are

GenesisTissue Inc. was founded in 2024 with the goal of revolutionizing regenerative tissues. GenesisTissue is a 3D bioprinting tissue company focused on designing and manufacturing personalized regenerative tissue implants for humans. We see a future where technology and biology come together to restore form and function. Using our proprietary 3D bioprinting and material science, we can finally move beyond implants made from legacy industrial materials, and towards living, regenerative solutions.

Our First Mission

A degradable, bioprinted breast tissue scaffold personalized for each patient, with the ability to become 100% native tissue in the breast.

367k

60%

1 in 5

women diagnosed with breast cancer

* 1

of women who undergo breast surgery have a portion of their breast removed through breast-conserving procedures, (i.e. lumpectomies)

* 2

patients need reoperations after initial lumpectomy surgery due to positive cancer margins

* 3

162k

* 4

breast reconstructive surgical procedures

305k

breast augmentations for cosmetic purposes

* 4

67k

breast implant removals. 41k from augmentation patients and 26k from reconstructive patients

* 4

* In the US, annually

1. American Cancer Society. Breast Cancer Facts & Figures 2024-2025.https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf

2. Nelson, Jonas A et al. “Analysis of a Trend Reversal in US Lumpectomy Rates From 2005 Through 2017 Using 3 Nationwide Data Sets.” JAMA surgery vol. 157,8 (2022): 702-711. doi:10.1001/jamasurg.2022.2065

3. McEvoy, Maureen P et al. “Update of the American Society of Breast Surgeons Toolbox to address the lumpectomy reoperation epidemic.” Gland surgery vol. 7,6 (2018): 536-553. doi:10.21037/gs.2018.11.03

4. American Society of Plastic Surgeons. 2024 ASPS Procedural Statistics Release. https://www.plasticsurgery.org/documents/news/statistics/2024/plastic-surgery-statistics-report-2024.pdf

3D Bioprinting

Biomaterial Innovation

Personalized Design

Technologies

Our platform combines precision 3D bioprinting, biomaterial innovation, and personalized design.

Meet Our Team

Katie Weimer - MS, MBA

CEO and Co-founder

As one of the world’s experts in 3D printing for healthcare, Katie has led advanced R&D, product and business development, and manufacturing operations with integrated regulatory processes. Additionally, she has supported over 100 FDA-cleared and CE-marked medical devices used worldwide. As a recognized expert in 3D printing and bioprinting, Katie has published over 15 peer-reviewed articles and holds two patents in the field.